Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. März 2012 09:00 ET | Quelle: INSYS Therapeutics, Inc.

INSYS Therapeutics Announces the Availability of SUBSYS(TM) (fentanyl sublingual spray) for Breakthrough Cancer Pain

PHOENIX, AZ--(Marketwire - Mar 26, 2012) - INSYS Therapeutics, Inc. (PINKSHEETS: NEOL) announces the launch of SUBSYS™ (fentanyl sublingual spray) indicated for the management of breakthrough...
05. Januar 2012 07:30 ET | Quelle: INSYS Therapeutics, Inc.

INSYS Therapeutics Announces FDA Approval of SUBSYS(R) Fentanyl Sublingual Spray

PHOENIX, AZ--(Marketwire - Jan 5, 2012) - INSYS Therapeutics (PINKSHEETS: NEOL) announces the US Food and Drug Administration approval of its branded breakthrough cancer pain medication,...
05. Dezember 2011 09:00 ET | Quelle: INSYS Therapeutics, Inc.

INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team

PHOENIX, AZ--(Marketwire - Dec 5, 2011) - INSYS Therapeutics (PINKSHEETS: NEOL) announces the addition of Matthew Napoletano as Vice President of Marketing to their commercial product team. He will...
01. November 2011 17:11 ET | Quelle: INSYS Therapeutics

INSYS Therapeutics Announces Commercial Team Additions

PHOENIX, AZ--(Marketwire - Nov 1, 2011) - INSYS Therapeutics (PINKSHEETS: NEOL) announces the addition of Shawn Simon as Vice President of Sales, and Becky Gamble as Vice President of Managed...